Gland Pharma Limited (BOM:543245)

Gland Pharma Balance Sheet

Financials in millions INR. Fiscal year is April - March.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021
Cash & Equivalents	25,562	3,571	19,089	3,188	4,925
Short-Term Investments	4,936	15,817	18,539	27,720	25,107
Trading Asset Securities	-	-	-	1,549	-
Cash & Short-Term Investments	30,498	19,388	37,628	32,457	30,031
Cash Growth	57.31%	-48.48%	15.93%	8.08%	128.86%
Accounts Receivable	15,165	16,482	9,587	12,097	6,710
Other Receivables	-	641.42	771.8	825.85	732.4
Receivables	15,165	17,123	10,360	12,928	7,445
Inventory	16,852	16,763	19,782	12,292	12,882
Prepaid Expenses	-	384.65	138.22	141.61	108.83
Other Current Assets	5,314	2,793	1,100	702.63	769.81
Total Current Assets	67,829	56,452	69,008	58,521	51,236
Property, Plant & Equipment	39,439	38,302	17,361	16,804	12,920
Long-Term Investments	-	6,545	-	2,000	-
Goodwill	2,482	2,423	-	-	-
Other Intangible Assets	1,057	1,122	116.61	125.35	-
Long-Term Deferred Tax Assets	520.68	504.37	-	-	-
Other Long-Term Assets	921.19	1,265	1,290	886.04	804.02
Total Assets	112,249	106,612	87,775	78,336	64,961
Accounts Payable	8,204	8,627	5,874	4,629	3,963
Accrued Expenses	-	1,385	477.42	461.14	358.33
Short-Term Debt	-	1,671	-	-	-
Current Portion of Long-Term Debt	1,916	461.21	5.6	1.12	1.35
Current Portion of Leases	150.32	177.05	1.49	1.49	1.62
Current Income Taxes Payable	736.88	516.37	9.85	179.79	286.9
Current Unearned Revenue	-	344.92	8.12	8.87	7.37
Other Current Liabilities	4,642	800.72	915.35	539.34	506.22
Total Current Liabilities	15,648	13,984	7,291	5,820	5,125
Long-Term Debt	776.64	1,065	32.61	38.21	39.34
Long-Term Leases	294.87	346.79	4.83	6.61	7.64
Long-Term Unearned Revenue	413.85	404.86	-	-	-
Long-Term Deferred Tax Liabilities	2,148	2,201	842.03	877.6	738.81
Other Long-Term Liabilities	1,460	298.28	17.33	17.33	17.33
Total Liabilities	20,742	19,374	8,188	6,760	5,928
Common Stock	164.76	164.71	164.7	164.3	163.59
Additional Paid-In Capital	-	19,292	19,284	18,954	18,401
Retained Earnings	-	67,910	60,185	52,375	40,258
Comprehensive Income & Other	91,343	-128.27	-46.81	83.32	209.71
Shareholders' Equity	91,507	87,238	79,587	71,576	59,032
Total Liabilities & Equity	112,249	106,612	87,775	78,336	64,961
Total Debt	3,137	3,722	44.53	47.43	49.95
Net Cash (Debt)	27,361	15,666	37,584	32,410	29,982
Net Cash Growth	74.65%	-58.32%	15.96%	8.10%	129.53%
Net Cash Per Share	166.08	95.10	228.22	196.97	189.42
Filing Date Shares Outstanding	164.79	164.71	164.7	164.3	163.59
Total Common Shares Outstanding	164.79	164.71	164.7	164.3	163.59
Working Capital	52,181	42,468	61,717	52,701	46,111
Book Value Per Share	555.30	529.65	483.22	435.64	360.85
Tangible Book Value	87,968	83,694	79,471	71,451	59,032
Tangible Book Value Per Share	533.82	508.13	482.51	434.87	360.85
Land	-	9,305	634.58	627.07	435.68
Buildings	-	5,934	3,328	3,203	2,492
Machinery	-	30,449	18,844	16,940	11,366
Construction In Progress	-	2,379	1,772	1,807	3,378

Source: S&P Global Market Intelligence. Standard template. Financial Sources.